Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...

AstraZeneca’s CEO Pascal Soriot has dismissed continued rumours about his departure as “fake news” as the company announced full year results showing sales growth for the first time in a decade.

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...